KALA - Oxford Finance provides $125M credit facility to Kala Pharmaceuticals

Oxford Finance announces the closing of a $125M senior secured term loan with Kala Pharmaceuticals ([[KALA]] -0.1%).Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophthalmic products.Kala is marketing two approved ophthalmology products, EYSUVIS for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease (“DED”), and INVELTYS for the treatment of post-operative inflammation and pain following ocular surgery.

For further details see:

Oxford Finance provides $125M credit facility to Kala Pharmaceuticals